Veru Revenue and Competitors
Estimated Revenue & Valuation
- Veru's estimated annual revenue is currently $18.8M per year.
- Veru's estimated revenue per employee is $155,000
Employee Data
- Veru has 121 Employees.
Veru's People
Name | Title | Email/Phone |
---|---|---|
1 | Chairman, CEO, and President | Reveal Email/Phone |
2 | Chief Business Officer | Reveal Email/Phone |
3 | Chief Scientific Officer | Reveal Email/Phone |
4 | Vice Chairman, Chief Corporate Officer | Reveal Email/Phone |
5 | CFO and CAO | Reveal Email/Phone |
6 | EVP, Global Clinical Operations | Reveal Email/Phone |
7 | EVP - Deputy General Counsel | Reveal Email/Phone |
8 | VP Head Medical Affairs | Reveal Email/Phone |
9 | EVP | Reveal Email/Phone |
10 | Head Quality Assurance, North America | Reveal Email/Phone |
Veru Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is Veru?
N/A
Total Funding
121
Number of Employees
$18.8M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Veru News
2022-04-17 - Is Veru Stock a Buy Now?
Veru (NASDAQ: VERU) is a bit of an oddball in biotech. It's developing medicines for breast cancer and treatment-resistant prostate cancer,...
2022-04-13 - Veru Stock Could Hit $36, Says Oppenheimer
Avid stock market watchers will know the biotech space operates according to a different rule set. One session can wipe off a huge chunk of...
2022-04-06 - Veru's Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized
Patients in Interim Analysis of Phase ...
Independent Data Monitoring Committee Unanimously Recommends that Phase 3 Clinical Trial for Sabizabulin for Treatment of Hospitalized...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $18.4M | 121 | 14% | $68M |
#2 | $36.9M | 121 | 49% | N/A |
#3 | $25.4M | 121 | 19% | N/A |
#4 | $16.9M | 121 | -2% | N/A |
#5 | $39.3M | 121 | 14% | N/A |